Literature DB >> 21646541

Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis.

Xiaodong Ma1, Munish Kumar, Saibyasachi N Choudhury, Lindsey E Becker Buscaglia, Juanita R Barker, Keerthy Kanakamedala, Mo-Fang Liu, Yong Li.   

Abstract

MicroRNA 21 (miR-21) is overexpressed in virtually all types of carcinomas and various types of hematological malignancies. To determine whether miR-21 promotes tumor development in vivo, we knocked out the miR-21 allele in mice. In response to the 7,12-dimethylbenz[a]anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate mouse skin carcinogenesis protocol, miR-21-null mice showed a significant reduction in papilloma formation compared with wild-type mice. We revealed that cellular apoptosis was elevated and cell proliferation was decreased in mice deficient of miR-21 compared to wild-type animals. In addition, we found that a large number of validated or predicted miR-21 target genes were up-regulated in miR-21-null keratinocytes, which are precursor cells to skin papillomas. Specifically, up-regulation of Spry1, Pten, and Pdcd4 when miR-21 was ablated coincided with reduced phosphorylation of ERK, AKT, and JNK, three major downstream effectors of Ras activation that plays a predominant role in DMBA-initiated skin carcinogenesis. These results provide in vivo evidence that miR-21 exerts its oncogenic function through negatively regulating its target genes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21646541      PMCID: PMC3121848          DOI: 10.1073/pnas.1103735108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

Review 1.  RAS oncogenes: the first 30 years.

Authors:  Marcos Malumbres; Mariano Barbacid
Journal:  Nat Rev Cancer       Date:  2003-06       Impact factor: 60.716

2.  Identification of hundreds of conserved and nonconserved human microRNAs.

Authors:  Isaac Bentwich; Amir Avniel; Yael Karov; Ranit Aharonov; Shlomit Gilad; Omer Barad; Adi Barzilai; Paz Einat; Uri Einav; Eti Meiri; Eilon Sharon; Yael Spector; Zvi Bentwich
Journal:  Nat Genet       Date:  2005-06-19       Impact factor: 38.330

3.  RalGDS is required for tumor formation in a model of skin carcinogenesis.

Authors:  Ana González-García; Catrin A Pritchard; Hugh F Paterson; Georgia Mavria; Gordon Stamp; Christopher J Marshall
Journal:  Cancer Cell       Date:  2005-03       Impact factor: 31.743

4.  Susceptibility of 129/SvEv mice in two-stage carcinogenesis protocols to 12-O-tetradecanoylphorbol-13-acetate promotion.

Authors:  J J Reiners; K P Singh
Journal:  Carcinogenesis       Date:  1997-03       Impact factor: 4.944

5.  Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis.

Authors:  M Quintanilla; K Brown; M Ramsden; A Balmain
Journal:  Nature       Date:  1986 Jul 3-9       Impact factor: 49.962

6.  Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis.

Authors:  Aaron P Jansen; Corinne E Camalier; Nancy H Colburn
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

7.  Mammalian sprouty proteins inhibit cell growth and differentiation by preventing ras activation.

Authors:  I Gross; B Bassit; M Benezra; J D Licht
Journal:  J Biol Chem       Date:  2001-10-03       Impact factor: 5.157

8.  Upregulation of miR-21 by Ras in vivo and its role in tumor growth.

Authors:  D Frezzetti; M De Menna; P Zoppoli; C Guerra; A Ferraro; A M Bello; P De Luca; C Calabrese; A Fusco; M Ceccarelli; M Zollo; M Barbacid; R Di Lauro; G De Vita
Journal:  Oncogene       Date:  2010-10-18       Impact factor: 9.867

9.  Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN.

Authors:  V Stambolic; A Suzuki; J L de la Pompa; G M Brothers; C Mirtsos; T Sasaki; J Ruland; J M Penninger; D P Siderovski; T W Mak
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

Review 10.  The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis--thirty-third G. H. A. Clowes Memorial Award Lecture.

Authors:  S H Yuspa
Journal:  Cancer Res       Date:  1994-03-01       Impact factor: 12.701

View more
  103 in total

1.  An integrative transcriptomic analysis reveals p53 regulated miRNA, mRNA, and lncRNA networks in nasopharyngeal carcinoma.

Authors:  Zhaojian Gong; Qian Yang; Zhaoyang Zeng; Wenling Zhang; Xiayu Li; Xuyu Zu; Hao Deng; Pan Chen; Qianjin Liao; Bo Xiang; Ming Zhou; Xiaoling Li; Yong Li; Wei Xiong; Guiyuan Li
Journal:  Tumour Biol       Date:  2015-10-13

2.  The Grainyhead transcription factor Grhl3/Get1 suppresses miR-21 expression and tumorigenesis in skin: modulation of the miR-21 target MSH2 by RNA-binding protein DND1.

Authors:  A Bhandari; W Gordon; D Dizon; A S Hopkin; E Gordon; Z Yu; B Andersen
Journal:  Oncogene       Date:  2012-05-21       Impact factor: 9.867

3.  Argonaute protein as a linker to command center of physiological processes.

Authors:  Kaifa Wei; Lingjuan Wu; Yanhui Chen; Yina Lin; Yanmei Wang; Xiaoyao Liu; Daoxin Xie
Journal:  Chin J Cancer Res       Date:  2013-08       Impact factor: 5.087

4.  Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target.

Authors:  Marianne Hütt-Cabezas; Matthias A Karajannis; David Zagzag; Smit Shah; Iren Horkayne-Szakaly; Elisabeth J Rushing; J Douglas Cameron; Deepali Jain; Charles G Eberhart; Eric H Raabe; Fausto J Rodriguez
Journal:  Neuro Oncol       Date:  2013-11-06       Impact factor: 12.300

5.  The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines.

Authors:  M Fragni; S A Bonini; P Bettinsoli; S Bodei; D Generali; A Bottini; P F Spano; M Memo; S Sigala
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-02-24       Impact factor: 3.000

6.  Comparative profiling of miRNA expression of lung adenocarcinoma cells in two-dimensional and three-dimensional cultures.

Authors:  Cui Li; Hong T Nguyen; Yan Zhuang; Zhen Lin; Erik K Flemington; Ying Zhuo; Stephen P Kantrow; Gilbert F Morris; Deborah E Sullivan; Bin Shan
Journal:  Gene       Date:  2012-10-02       Impact factor: 3.688

7.  Anti-inflammatory effects of miR-21 in the macrophage response to peritonitis.

Authors:  Rebecca Elise Barnett; Daniel J Conklin; Lindsey Ryan; Robert C Keskey; Vikram Ramjee; Ernesto A Sepulveda; Sanjay Srivastava; Aruni Bhatnagar; William G Cheadle
Journal:  J Leukoc Biol       Date:  2015-09-17       Impact factor: 4.962

8.  Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway.

Authors:  Xiaodong Ma; Saibyasachi N Choudhury; Xiang Hua; Zhongping Dai; Yong Li
Journal:  Carcinogenesis       Date:  2013-02-05       Impact factor: 4.944

9.  Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes.

Authors:  Joanne Ngeow; Xin He; Jessica L Mester; Junying Lei; Todd Romigh; Mohammed S Orloff; Mira Milas; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2012-10-12       Impact factor: 5.958

10.  Strand-specific in vivo screen of cancer-associated miRNAs unveils a role for miR-21(∗) in SCC progression.

Authors:  Yejing Ge; Liang Zhang; Maria Nikolova; Boris Reva; Elaine Fuchs
Journal:  Nat Cell Biol       Date:  2015-11-30       Impact factor: 28.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.